» Articles » PMID: 26174476

Prediction of Outcomes by Early Treatment Responses in Childhood T-cell Acute Lymphoblastic Leukemia: a Retrospective Study in China

Overview
Journal BMC Pediatr
Publisher Biomed Central
Specialty Pediatrics
Date 2015 Jul 16
PMID 26174476
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Early treatment responses are important prognostic factors in childhood T-cell acute lymphoblastic leukemia (T-ALL) patients. The predictive values of early treatment responses in Chinese childhood T-ALL patients were still unknown.

Methods: From January 2003 to December 2012, 74 consecutive patients aged ≤ 15 years with newly diagnosed T-ALL were treated with BCH-2003 protocol or CCLG-2008 protocol in the Department of Pediatric, Institute of Hematology and Blood Diseases Hospital in China. Predictive values of early treatment responses, including prednisone response, bone marrow morphology at day 15 and day 33 during induction chemotherapy, and minimal residual disease (MRD) monitored by flow cytometry after induction therapy (time point 1, TP1) and before consolidation therapy (time point 2, TP2), were analyzed.

Results: The 5-year event free survival (EFS) and overall survival (OS) rates for these patients were 62.5% (SE, 6.4) and 62.7% (SE, 6.6), respectively. Prednisone poor responder was strongly associated with increased chance of induction failure (14.8%) and decreased survival rate (5 year EFS rate, 51.1 % (SE, 10.5)). Patients with ≥ 25% blast cells in bone marrow at day 15 were more likely to have an inferior outcome. 93.2% of the T-ALL patients achieved complete remission at day 33 while patients with resistant disease all died of disease progression. MRD ≥ 10(-2) at TP1 or MRD ≥ 10(-3) at TP2 was significantly related to dismal prognosis. Risk groups classified by MRD at two time points could stratify patients into different groups: 29.0% of the patients were MRD standard risk (MRD < 10(-4) at both time points) with 3-year EFS rate of 100%, 29.0% were MRD high risk (MRD ≥ 10(-2) at TP1 or MRD ≥ 10(-2) at TP2) with 3-year EFS rate of 55.6% (SE, 16.6) , and the rest of patients were defined as MRD intermediate risk with 3-year EFS rate of 85.7% (SE, 13.2).

Conclusion: Our study demonstrated that MRD was the most powerful predictor of treatment outcome in childhood T-ALL patients and conventional morphological assessments of treatment response still played important roles in predicting treatment outcome and tailoring treatment intensity especially in countries with inadequate skills or financial resources for MRD monitoring.

Citing Articles

Survival and Treatment Outcomes of Childhood Acute Lymphoblastic Leukemia in a Low-Middle Income Country: A Single-Center Experience in West Java, Indonesia.

Ramadhan M, Sari N, Peryoga S, Susanah S J Blood Med. 2024; 15:77-85.

PMID: 38405084 PMC: 10887884. DOI: 10.2147/JBM.S438042.


Integrated genomic analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia.

Zhu H, Dong B, Zhang Y, Wang M, Rao J, Cui B Blood Sci. 2022; 4(1):16-28.

PMID: 35399540 PMC: 8974951. DOI: 10.1097/BS9.0000000000000102.


A Novel Risk Defining System for Pediatric T-Cell Acute Lymphoblastic Leukemia From CCCG-ALL-2015 Group.

Liu X, Zou Y, Zhang L, Guo Y, Chen Y, Yang W Front Oncol. 2022; 12:841179.

PMID: 35296004 PMC: 8920043. DOI: 10.3389/fonc.2022.841179.


Early T-cell precursor acute lymphoblastic leukemia and other subtypes: a retrospective case report from a single pediatric center in China.

Liu X, Zou Y, Zhang L, Chen X, Yang W, Guo Y J Cancer Res Clin Oncol. 2021; 147(9):2775-2788.

PMID: 33651142 DOI: 10.1007/s00432-021-03551-4.


Childhood T-cell acute lymphoblastic leukemia in a single Latin American center: impact of improved treatment scheme and support therapy on survival.

Jaime-Perez J, Hernandez-De Los Santos J, Gomez-Almaguer D Hematol Transfus Cell Ther. 2019; 42(4):320-325.

PMID: 31810895 PMC: 7599264. DOI: 10.1016/j.htct.2019.09.005.


References
1.
Reiter A, Schrappe M, Ludwig W, Hiddemann W, Sauter S, Henze G . Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994; 84(9):3122-33. View

2.
Brisco M, Condon J, Hughes E, Neoh S, Sykes P, Seshadri R . Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet. 1994; 343(8891):196-200. DOI: 10.1016/s0140-6736(94)90988-1. View

3.
Arico M, Basso G, Mandelli F, Rizzari C, Colella R, Barisone E . Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Cancer. 1995; 75(7):1684-93. DOI: 10.1002/1097-0142(19950401)75:7<1684::aid-cncr2820750720>3.0.co;2-2. View

4.
Gaynon P, Desai A, Bostrom B, Hutchinson R, Lange B, Nachman J . Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer. 1997; 80(9):1717-26. DOI: 10.1002/(sici)1097-0142(19971101)80:9<1717::aid-cncr4>3.0.co;2-b. View

5.
Uckun F, Sensel M, Sun L, Steinherz P, Trigg M, Heerema N . Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood. 1998; 91(3):735-46. View